BGA
TPST icon

Belmont Global Advisors’s Tempest Therapeutics TPST Stock Holding History

Belmont Global Advisors’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-17
Closed -$2.21M – 105
2014
Q4 		$2.21M Buy
17
+5
+42% +$366K 2.18% 12
2014
Q3 		$581K Hold
12
– – 0.46% 61
2014
Q2 		$321K Buy
+12
New +$283K 0.23% 93

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OH
Orbis Holdings Hamilton, Bermuda $12.8B AUM 8.29% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Belmont Global Advisors's TPST Position: Q1 2015 in Review

Belmont Global Advisors sold out of Tempest Therapeutics (TPST) in Q1 2015, closing a stake of 17 shares — an estimated $2.21M sold.

Belmont Global Advisors first reported a position in TPST in Q2 2014 and held it in 3 quarters. The position peaked at $2.21M in Q4 2014. 86 funds tracked by Wall St. Rank hold TPST as of Q1 2015.

  • Belmont Global Advisors reported no remaining Tempest Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Belmont Global Advisors sold 17 Tempest Therapeutics shares in Q1 2015, an estimated $2.21M.
  • Belmont Global Advisors first reported a position in Tempest Therapeutics in Q2 2014 and held it in 3 quarters.
  • Belmont Global Advisors's Tempest Therapeutics position peaked at $2.21M in Q4 2014.
  • 86 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2015.

Based on Belmont Global Advisors's 13F filing for Q1 2015, filed 15 May 2015.